Prometheus grants oncology program to Clinipace
As part of the contract, Clinipace Worldwide will study Proleukin (aldesleukin) and Vemurafenib therapy in patients with metastatic melanoma (mM). The study with a sample size of 135
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).